Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H27N3O6.ClH |
Molecular Weight | 441.906 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O
InChI
InChIKey=LSLQGMMMRMDXHN-GEUPQXMHSA-N
InChI=1S/C20H27N3O6.ClH/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28;/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26);1H/t13-,15-,16-;/m0./s1
DescriptionSources: https://www.drugs.com/uk/pdf/leaflet/815031.pdfCurator's Comment: Description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/31738
http://patient.info/medicine/imidapril-for-high-blood-pressure-tanatril
https://www.ncbi.nlm.nih.gov/pubmed/17547476
Sources: https://www.drugs.com/uk/pdf/leaflet/815031.pdf
Curator's Comment: Description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/31738
http://patient.info/medicine/imidapril-for-high-blood-pressure-tanatril
https://www.ncbi.nlm.nih.gov/pubmed/17547476
Imidapril (Tanatril), through its active metabolite imidaprilat, acts as an ACE inhibitor to suppress the conversion of angiotensin I to angiotensin II and thereby reduce total peripheral resistance and systemic blood pressure (BP). In clinical trials, oral imidapril was an effective antihypertensive agent in the treatment of mild to moderate essential hypertension. Some evidence suggests that imidapril also improves exercise capacity in patients with chronic heart failure (CHF) and reduces urinary albumin excretion rate in patients with type 1 diabetes mellitus. Imidapril was well tolerated, with a lower incidence of dry cough than enalapril or benazepril, and is a first choice ACE inhibitor for the treatment of mild to moderate essential hypertension.
CNS Activity
Sources: http://www.medscape.org/viewarticle/493130_7
Curator's Comment: non-brain-penetrating ACE inhibitor
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096989 |
|||
Target ID: CHEMBL1808 |
9.9 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Tanatril Approved UseTanatril is indicated for the treatment of essential hypertension in adults Launch Date2007 |
Sample Use Guides
Adult: PO Initial: 5 mg once daily at bedtime. Maintenance: 10 mg/day. Max: 20 mg/day. Should be taken on an empty stomach. Take 15 min before meals. However, when initiating therapy, 1st dose should be given at bedtime.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2913292
Imidapril inhibited activity on Angiotensin I converting enzyme (ACE) obtained from pig renal cortex with IC50 9.9uM
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7NSF9GG1NU
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | |||
|
DTXSID7046912
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | |||
|
SUB02642MIG
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | |||
|
259335
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | RxNorm | ||
|
C99550
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL317094
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | |||
|
m6222
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | Merck Index | ||
|
89396-94-1
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | |||
|
DBSALT002072
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | |||
|
100000092320
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY | |||
|
5485193
Created by
admin on Fri Dec 15 16:02:40 GMT 2023 , Edited by admin on Fri Dec 15 16:02:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD